Published 3 years ago

FTC Challenges Illumina’s Planned Acquisition of Liquid-Biopsy Firm Grail

Summary

The Federal Trade Commission filed a lawsuit Tuesday that seeks to block Illumina Inc.’s planned $7.1 billion acquisition of a developer of a long-sought blood test that promises to detect cancer early.

0 Articles

All

Left

Center

Right

Yahoo News

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina commits to pursuing GRAIL acquisition to accelerate access to breakthrough multi-cancer early detection blood test.

3 years ago·Los Angeles, United States

Read Full Article

Reuters

U.S. FTC seeks to stop Illumina's proposed purchase of Grail

The Federal Trade Commission will seek to stop Illumina Inc's $7.1 billion proposed acquisition of cancer detection test maker Grail, the agency said in a statement on Tuesday.

3 years ago·United Kingdom

Read Full Article

Business Insider

FTC Seeks To Block Illumina's Proposed $7.1 Bln Acquisition Of Grail

(RTTNews) - The U.S. Federal Trade Commission or FTC has challenged Illumina Inc.'s proposed $7.1 billion acquisition of cancer detection test mak...

3 years ago·United States

Read Full Article

Business Wire

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina commits to pursuing GRAIL acquisition to accelerate access to breakthrough multi-cancer early detection blood test.

3 years ago·Crystal River, United States

Read Full Article

Wall Street Journal

FTC Challenges Illumina’s Planned Acquisition of Liquid-Biopsy Firm Grail

The Federal Trade Commission said it would seek to block Illumina Inc.’s planned $7.1 billion acquisition of a developer of a long-sought blood test that promises to detect cancer early.

3 years ago·New York, United States

Read Full Article